US Bancorp DE Has $368,000 Stock Position in CareDx, Inc (NASDAQ:CDNA)

US Bancorp DE raised its stake in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 907.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,168 shares of the company's stock after purchasing an additional 15,464 shares during the period. US Bancorp DE's holdings in CareDx were worth $368,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Quarry LP acquired a new position in shares of CareDx during the 3rd quarter worth about $27,000. Harvest Fund Management Co. Ltd bought a new position in CareDx in the 3rd quarter worth approximately $52,000. KBC Group NV acquired a new position in shares of CareDx during the third quarter worth approximately $99,000. Quest Partners LLC boosted its position in shares of CareDx by 37.8% in the third quarter. Quest Partners LLC now owns 5,611 shares of the company's stock valued at $175,000 after acquiring an additional 1,540 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in shares of CareDx in the third quarter worth $271,000.

Analysts Set New Price Targets

Several equities analysts recently commented on CDNA shares. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and cut their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. Stephens reiterated an "overweight" rating and set a $40.00 price target on shares of CareDx in a research note on Thursday, February 27th. Finally, HC Wainwright dropped their price target on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.83.

Remove Ads

CareDx Price Performance

Shares of NASDAQ:CDNA traded up $0.37 during midday trading on Monday, reaching $19.27. The company's stock had a trading volume of 672,665 shares, compared to its average volume of 836,347. The business's fifty day simple moving average is $22.24 and its 200-day simple moving average is $24.31. The company has a market capitalization of $1.07 billion, a P/E ratio of -7.14 and a beta of 1.95. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The business had revenue of $86.58 million for the quarter, compared to analysts' expectations of $84.56 million. On average, analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.